(a) A pharmacist acting in good faith and exercising reasonable care may, without a prescriber-patient relationship, prescribe an opiate antagonist to: - (i) A person at risk of experiencing an opiate related drug overdose, such as:
- (A) Current use or a history of using illicit or prescription opioids;
- (B) A new prescription for an opioid to treat a new condition such as trauma or surgery related pain;
- (C) Concurrent prescriptions for an opioid plus other medications that may cause respiratory depression;
- (D) Persons with respiratory, hepatic or renal impairment who are prescribed an opioid;
- (E) Persons mixing opioids with alcohol;
- (F) Persons recently leaving a correctional or rehab facility; or
- (G) Persons taking opioids for ? 30 days.
- (ii) A person in a position to assist a person at risk of experiencing an opiate related drug overdose; or
- (iii) A person who, in the course of the person's official duties or business, may encounter a person experiencing an opiate related drug overdose.
(b) A pharmacist who prescribes an opiate antagonist shall provide appropriate counseling and written instruction to the person to whom the opiate antagonist is prescribed, including: - (i) How to prevent an opiate related drug overdose;
- (ii) How to recognize an opiate related drug overdose;
- (iii) How to respond appropriately to an opiate related drug overdose;
- (iv) How to administer an opiate antagonist;
- (v) Naloxone is an opiate antagonist (blocker) that may reverse the effects of opioids within two (2) to three (3) minutes of administration;
- (vi) Naloxone is not abusable, nor is it a controlled substance;
- (vii) Effects of naloxone may only last thirty (30) minutes;
- (viii) Opioid dependent persons will be sent into withdrawal; and
- (ix) Ensuring that the person to whom an opiate antagonist has been administered receives, as soon as possible, additional medical care and a medical evaluation.
(c) If the person to whom the opiate antagonist would be administered has a known hypersensitivity to naloxone, the pharmacist should not prescribe nor dispense naloxone.
(d) Prior to prescribing naloxone, a pharmacist shall successfully complete a minimum of one hour of an approved continuing education program specific to the use of naloxone.
(e) The prescribing pharmacist shall generate a written or electronic prescription for any naloxone dispensed, as follows: - (i) Record themselves as the prescriber;
- (ii) Maintain the prescription for two years; and
- (iii) Report the dispensing to the Wyoming prescription drug monitoring program (WORx) as required by the Wyoming Controlled Substances Act Rules Chapter 8.
059-18 Wyo. Code R. § 18-6
Adopted, Eff. 10/31/2017.